Vividion Therapeutics names Aleksandra Rizo as President and Head of Research and Development
SAN DIEGO – June 23, 2022 – Vividion Therapeutics, Inc., a biopharmaceutical company using recent discovery technologies to free up high worth, historically undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a completely owned and independently operated subsidiary of Bayer AG, on the brand new time launched that Aleksandra Rizo, M.D., Ph.D., shall be a part of the corporate as President and Head of Research and Pattern. Dr. Rizo brings intensive alternate leadership experience to Vividion, having held multiple senior govt roles all thru her occupation at each biotechnology and enormous pharmaceutical firms.
“Aleksandra brings confirmed govt leadership skills, deep translational and scientific vogue experience, and the flexibility to attain each extensive and runt company cultures,” said Jeffrey Hatfield, chief govt officer of Vividion. “Her addition to our crew comes at an thrilling inflection point for our development, as we clearly heed the functionality to advance multiple programs into the sanatorium starting subsequent year.”
“I’m very enraged to affix Vividion to proceed to advance innovation in an entrepreneurial atmosphere pondering about patient advantages and outcomes,” said Dr. Rizo. “I’m impressed by the pipeline’s breadth of recent, first-in-class programs in oncology and immunology. These programs are only about all concentrated on proteins the alternate has beforehand viewed as undruggable and indicate the functionality to recount huge worth to sufferers if a success. I’m additionally intrigued by the innovative alternate mannequin established with Bayer that enables us to operate largely autonomously and independently but with the technical experience and financial stability of a significant pharmaceutical company.”
Dr. Rizo has served most recently as Executive Vice President and Chief Medical Officer of Geron Corporation since January 2019 where she equipped leadership and direction for all scientific and translational efforts. Incorporated in her reporting duties had been scientific vogue, scientific operations, scientific pharmacology, biometrics, translational research, program management and medical affairs. Prior to joining Geron, Dr. Rizo modified into as soon as Executive Director, Device and Scientific Lead, at Celgene Corporation from March 2018 to January 2019, where she led submission actions and participated in strategic vogue actions in the Myeloid Therapeutic Build of dwelling. From October 2008 to March 2018, Dr. Rizo served in a assortment of oncology drug vogue functions with increasing duties at Janssen Research and Pattern, LLC (Janssen), together with Senior Director, Compound Pattern Team Leader for all myeloid sources, Senior Director, World Scientific Leader for the imetelstat, ibrutinib mantle cell lymphoma (MCL) program, and others. In these roles, she had oversight and leadership duties for overall scientific vogue strategy, glimpse designs, execution and records interpretation. To boot, Dr. Rizo modified into as soon as a core member of Janssen’s Hematology Device Team where she participated and led multiple diligence projects in hematology. At some stage in her preliminary tenure with Janssen, Dr. Rizo additionally worked on Velcade scientific trials in lymphoma and multiple myeloma. Dr. Rizo holds an M.D. from the College Ss Cyril and Methodius, Skopje, Macedonia, where she additionally accomplished a residency in inner medication/hematology. She additionally has a Ph.D. in human leukemic stem cell biology from the College of Groningen, Groningen, Netherlands, and a Ph.D. in mouse stem cell biology from the College of Tokyo, Tokyo, Japan.
About Vividion
Vividion Therapeutics, Inc. a completely owned and independently operated subsidiary of Bayer AG obtained in August 2021, is a biopharmaceutical company using recent discovery technologies to free up high worth, historically undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to title hundreds of beforehand unknown functional pockets on well-validated protein targets implicated in a extensive assortment of ailments, whereas simultaneously figuring out compounds from its proprietary covalent chemistry library that work together in a extremely selective formula with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a varied pipeline of extremely selective runt molecule therapeutics concentrated on high worth, historically undruggable targets in oncology and immunology. For more recordsdata, please talk over with www.vividion.com.
About Bayer
Bayer is a worldwide project with core competencies in the existence science fields of health care and weight reduction program. Its products and providers and products are designed to succor other americans and the planet thrive by supporting efforts to master the significant challenges presented by a rising and aging global population. Bayer is committed to driving sustainable vogue and generating a certain affect with its businesses. At the identical time, the Community targets to amplify its incomes power and make worth thru innovation and development. The Bayer heed stands for belief, reliability and quality all thru the enviornment. In fiscal 2021, the Community employed spherical 100,000 other americans and had gross sales of 44.1 billion euros. R&D charges, earlier than special items, amounted to 5.3 billion euros. For more recordsdata, plod to www.bayer.com.
Secure more recordsdata at https://pharma.bayer.com/
Be conscious us on Facebook: http://www.fb.com/bayer
Be conscious us on Twitter: @BayerPharma
